Director / Editor: Victor Teboul, Ph.D.
Looking inside ourselves and out at the world
Independent and neutral with regard to all political and religious orientations,® aims to promote awareness of the major democratic principles on which tolerance is based.

'A slow and painful journey': why did it take over 20 years to approve the new Alzheimer's drug?

By Ralph N. Martins, Professor and Chair in Ageing and Alzheimer’s Disease, Edith Cowan University
Share this article
A new drug to treat Alzheimer’s disease was last week given accelerated approval by the United States Food and Drug Administration.

The drug is called aducanumab, commercially known as Aduhelm, and was developed by US biotechnology company Biogen.

This development is a game changer, because aducanumab is the first ever drug that targets the underlying cause of Alzheimer’s rather than simply the symptoms. Aducanumab is an antibody which

Read complete article

© The Conversation -

Follow us on ...
Facebook Twitter